Divi's Laboratories on Friday said it has inked a supply agreement with a global pharmaceuticals firm. Under the long-term agreement, the company will be manufacturing and supplying advanced intermediates as per the commercial terms agreed between the parties, Divi's Laboratories said in a regulatory filing.
The company expects meaningful revenue contribution from this long-term agreement, it added without disclosing the identity of the partner.
"The company is planning for capacity addition at its manufacturing facilities with an estimated investment between Rs 650 crore to Rs 700 crore, to be funded from internal accruals," it said.
Shares of the company were trading 2.07 per cent down at Rs 5,638.35 apiece on BSE.
The company expects meaningful revenue contribution from this long-term agreement, it added without disclosing the identity of the partner.
"The company is planning for capacity addition at its manufacturing facilities with an estimated investment between Rs 650 crore to Rs 700 crore, to be funded from internal accruals," it said.
Shares of the company were trading 2.07 per cent down at Rs 5,638.35 apiece on BSE.
You may also like
Hindu man abducted, beaten to death in Bangladesh
UP: Three killed, two injured in head-on bike collision in Etawah
Maharashtra Weather, April 19: Nagpur boils at 42.8°C; Check city-wise updates
Arvind Kejriwal's daughter Harshita ties the knot with Sambhav Jain, reception on April 20
Andhra: Tension builds in GVMC ahead of no-confidence motion against Mayor
